Company Description
Tiziana Life Sciences Ltd. operates as a clinical stage biotechnology company. It engages in the research and development of biotechnological and pharmaceutical products. The firm specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline in...
Tiziana Life Sciences Ltd. operates as a clinical stage biotechnology company. It engages in the research and development of biotechnological and pharmaceutical products. The firm specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple Sclerosis, Crohn's disease and KRAS+ NSCLC. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.
Valuation
Price to Book Ratio
2.38
Enterprise Value to EBITDA
-4.74
Total Debt to Enterprise Value
0.03
Efficiency
Income Per Employee
-2,927,125.00
Liquidity
Current Ratio
6.45
Quick Ratio
6.45
Cash Ratio
5.59
Profitability
Return on Assets
-39.16
Return on Equity
-45.14
Return on Total Capital
-54.35
Return on Invested Capital
-45.01
Capital Structure
Total Debt to Total Equity
3.28
Total Debt to Total Capital
3.18
Total Debt to Total Assets
2.78
Officers and Executives
| Name | Age | Officer Since | Title |
|---|---|---|---|
| Mr. Gabriele Marco Antonio Cerrone | 49 | 1998 | Executive Chairman |
| Dr. Vaseem A. Palejwala | - | 2017 | Senior Director-Clinical Operations |
| Ms. Keeren Shah | 46 | - | Finance Director |
| Dr. Matthew W. Davis | - | 2022 | Chief Medical & Scientific Officer |
| Mr. Paul Spencer | - | 2022 | Head-Business Development & Investor Relations |
Insider Actions
| 10/05/2021 |
Gabriele Marco Antonio Cerrone |
60,000 | Acquisition at $0.52 per share. | 31,050 |
| 10/04/2021 |
Gabriele Marco Antonio Cerrone |
60,000 | Acquisition at $0.55 per share. | 33,000 |
| 10/04/2021 |
Gabriele Marco Antonio Cerrone |
60,000 | Acquisition at $0.5 per share. | 30,000 |
| 10/01/2021 |
Gabriele Marco Antonio Cerrone |
37,500 | Acquisition at $0.49 per share. | 18,300 |
| 09/27/2021 |
Gabriele Marco Antonio Cerrone |
100,000 | Acquisition at $0.52 per share. | 52,000 |
| 05/20/2021 |
Gabriele Marco Antonio Cerrone |
10,000 | Acquisition at $0.71 per share. | 7,100 |
| 12/09/2020 |
Gabriele Marco Antonio Cerrone |
38,000 | Acquisition at $0.78 per share. | 29,640 |
| 11/18/2020 |
Gabriele Marco Antonio Cerrone |
45,000 | Acquisition at $0.84 per share. | 37,800 |
| 02/03/2020 |
Gabriele Marco Antonio Cerrone |
5,000 | Acquisition at $2.37 per share. | 11,850 |
| 01/13/2020 |
Gabriele Marco Antonio Cerrone |
28,500 | Acquisition at $0.43 per share. | 12,255 |
| 12/31/2019 |
Gabriele Marco Antonio Cerrone |
12,500 | Acquisition at $2.79 per share. | 34,875 |
MarketWatch News on TLSA
-
Tesla Hit a New High. No, It Was TLSA. Confused?
- Barron's Online
-
Tesla's stock drops 3.3% premarket, after soaring 9.0% Wednesday to record high
- Tomi Kilgore
Other News on TLSA
-
Stock Split Watch: Is Amazon Next?
- Motley Fool
-
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
- InvestorPlace.com
